Proceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005
|
|
- Edwina Baker
- 6 years ago
- Views:
Transcription
1 Close this window to return to IVIS Proceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005 Hosted by: Reprinted in the IVIS website with the permission of the WSAVA
2 Cutaneous Mast Cell Tumors in dogs Oncology Antony S Moore MVSc, Diplomate ACVIM (Oncology) Co-Director, Veterinary Oncology Consultants 379 Lake Innes Dr, Wauchope NSW 2446 ( Adjunct Professor, Institute of Veterinary Sciences, Massey University, New Zealand Abstract Canine mast cell tumors (MCT) vary greatly, and no prediction can be made for their behavior on clinical appearance alone. Important prognostic information can be gained from histologic grading and assessment of surgical margins. Surgical excision is indicated if the tumour is solitary and is the treatment of choice for grade 1 and 2 MCT. Excision should include a minimum 2cm margin around the borders of the tumor and one fascial plane below. Incomplete excision should be followed by further surgery, or by radiation therapy; both provide excellent long-term local control. Grade 3 or metastatic MCT are best treated by chemotherapy and/or palliative therapy. Active chemotherapy agents include vinblastine and lomustine (CCNU). Recent identification of mutations in tyrosine kinase receptors on MCT cells implies an exciting new therapeutic role for drugs that target these receptors. In dogs, mast cell tumors (MCTs) are most commonly found in the cutaneous tissue. In most dogs, tumors are solitary, but in about 6%, the tumors are multiple. Tumors usually occur in older dogs (mean age = 9 years) with no sex predilection. Boxers, Rhodesian ridgebacks, pugs, Boston terriers, pit-bull terriers and Weimaraners are at high risk (4 to 8 times more than the population) for developing MCTs. Shar-Peis, particularly young dogs, are predisposed to developing MCT, and these tumors are often poorly differentiated and aggressive biologically. It is uncommon to diagnose MCTs without skin involvement in dogs. Mast cell tumors vary greatly in appearance, and no estimate of their malignancy or prediction of their behavior can be made on clinical appearance alone. Some MCTs may be present for months to years before rapidly disseminating; others act aggressively from the beginning. Approximately 6% of dogs will develop multiple cutaneous MCT. Occasionally, mechanical manipulation during examination of this tumor causes degranulation of mast cells, producing erythema and wheal formations. This phenomenon has been observed in both dogs and cats (the Darier's sign ) and is considered of diagnostic significance. Owners may report that the tumor enlarges rapidly and then diminishes in size over a period of about 24 hours. Such a history should increase the clinician's suspicion of mast cell tumor. The clinical appearance of MCTs in dogs may vary widely but diagnosis is relatively easy using aspiration cytology. Presurgical aspiration of these tumors provides a cytology specimen characterized by round cells that may have well-stained and large cytoplasmic granules (well-differentiated) or that may be more anaplastic with small, poorly staining cytoplasmic granules. Eosinophils are often seen in aspirates of MCTs because of eosinophil chemotaxis to histamine release. Diagnosis of MCT often can be made by fine-needle aspiration cytology; but excisional biopsy is required for accurate histologic grading of the tumor. Histopathologic grading of the tumor has been correlated with both recurrence and survival. All dogs with MCTs should be staged to determine the extent of their disease. This is especially important for dogs being considered for aggressive surgery such as amputation, or radiation therapy. To establish the stage of a dog with a cutaneous MCT, the following information is needed: 1. Complete Blood Count (CBC), Serum Chemistry Profile and Urinalysis 2. Lymph Node Aspirates The clinician should perform fine-needle aspiration of the regional lymph node if the node is enlarged. The presence of clusters of mast cells (and eosinophils) is an indication that the MCT may no longer be confined to the primary site. Mast cells may infiltrate a regional lymph node in a dog with a MCT as an inflammatory response to the tumor, therefore a suspicious cytology result should be confirmed by biopsy. 3. Radiographs and Ultrasonography Splenomegaly or hepatomegaly may indicate spread of MCTs systemically. Pulmonary metastasis of MCTs is rare. Ultrasonography is most useful for staging a dog with MCT if used in conjunction with histopathology or cytology. 4. Bone Marrow Aspirates The presence of >1% mast cells indicates systemic spread of the neoplasm. In a recent report 4.5% of dogs
3 with cutaneous MCT had either >1% or abnormal mast cells in a bone marrow aspirate. 5. Miscellaneous Tests Fecal occult blood tests may be useful in evaluating patients with mast cell disease. In many cases, feces may contain small amounts of blood that are insufficient to produce melena. Evidence of gastrointestinal bleeding in a patient with a MCT should prompt the clinician to treat with medications that block the effects of mast cell hyperhistaminemia (i.e., H2 blockers, such as cimetidine, ranitidine, famotidine). 6. Buffy Coat Smears Care must be exercised in interpreting buffy coat smears, because mastocythemia has been reported in a variety of canine acute inflammatory diseases (see below). For this reason, some oncologists now feel that this test has limited applicability to staging of dogs with MCT. We no longer recommend it as part of staging for MCT. PROGNOSTIC FACTORS Recent clinical research has led to the identification of prognostic factors for dogs undergoing therapy with surgery and radiation therapy, and this same research has led to changes in thinking about other previously well-accepted prognostic factors. Gender: male dogs had a worse prognosis after chemotherapy treatment for MCT. Age: dogs older than 8 years were nearly 3 times more likely to die of their disease after treatment for MCT. Growth Rate: Dogs with tumors that grow at a rate greater than 1 cm per week appear to have a worse prognosis, in an early study of dogs treated with surgery alone. Tumor Grade: Recent studies using aggressive surgical technique, and histology to examine margins (rather than the surgeon's clinical impression), has shown that dogs with grade 2 MCT have a much lower rate of local recurrence and longer survival rates than was previously believed. Nonetheless grading is still an important prognostic factor. Grade 3 tumors are more likely to be incompletely excised, more likely to metastasize and nearly 4 times more likely to result in death than tumors of lower grades. Surgical Margins: The completeness of excision (i.e., whether the surgical margins are dirty ) is an important prognostic factor and also important in determining if further surgery or adjunctive radiation therapy is needed. There is often disparity between the surgeon's assessment of margins and those assessed by histopathology. In one study 22 of 59 tumors thought to have been excised widely had either questionable (10) or incomplete (12) excision based on histological examination. Dogs with incomplete excisions are more likely to develop metastatic disease. Because of this finding, and because tumor recurrence is still more common following incomplete excision, the clinician is counseled to obtain clear surgical margins wherever possible, and not to rely on a marginal excision. Tumor Location: Although it was often reported that MCT in the inguinal and perineal regions had a poor prognosis regardless of histologic grade, this has recently been shown to not always be true. Although MCTs in this location have long been thought to be more likely to recur than MCTs in other subcutaneous locations, aggressive local therapy often results in long-term control and there is no difference in recurrence rate, time to recurrence and survival compared to dogs with MCT at other locations. MCT of the muzzle were found to often be grade 3 tumors, and to have a higher rate of regional lymph node metastasis (nearly 60% of dogs evaluated). Multiple tumors: Although the staging scheme detailed above includes multiple tumors as being a higher clinical stage, the occurrence of multiple tumors has not been shown to be a worse prognostic factor. In a study that compared dogs with single MCT and dogs with multiple MCT, there was no significant difference in survival times between these two groups. It appears that the staging scheme should be amended to exclude multiple tumors in the category of stage 3. Tumor Stage: Dogs with lymph node metastases are nearly 8 times as likely to die of MCT. A potential problem with staging is that small numbers of mast cells may be found in the circulation, spleen, liver and bone marrow, so the significance of such a finding is unclear. In one study the presence of small numbers of mast cells in theses locations did not seem to influence survival in dogs with grade 2 MCTs. Mast cells may infiltrate a regional lymph node in a dog with a MCT as an inflammatory response to the tumor, therefore a suspicious cytology result should be confirmed by biopsy. TREATMENT Control of canine MCTs involves the use of surgery, chemotherapy, or radiation therapy, either individually or in combination. Surgery Surgical excision is indicated if the tumor is solitary and evidence of lymph node involvement or systemic spread is lacking. Excision should be wide and deep to a minimum margin of 2-3 cm around the perceived borders of the tumor and one fascial plane below. With this aggressive surgical approach, recurrence of grade 1 and grade 2 MCTs is very low. A recent study examined the completeness of surgical excision at margins 1cm, 2cm and 3cm from the edges of grade 1 and 2 MCT. All grade 1 tumors were excised 1 centimeter from the tumor borders, while only 75% of grade 2 tumors were completely excised at the same distance. All grade 2 tumors were excised 2cm from the tumor borders, leading the authors to speculate that it may be possible to completely excise MCT with these narrower than usually prescribed margins. As previously stated, surgical excision should be aggressive. All excised tissue should be examined histologically for completeness of tumor excision as described above under Prognostic Factors. If the tumor is grade 1 or grade 2 and excision is complete, no further treatment is necessary. Extension of the tumor beyond the surgical borders or a report of close margins (as defined above) should prompt wider excision
4 if this is possible. A second excision should include the previous excision site plus lateral margins of 2-3 cm and additional deep tissue. If the tumor cannot be completely excised due to tumor location or other factors, or if it is a grade 3 MCT, further therapy is indicated. The animal should be evaluated for radiation therapy, if available. Chemotherapy may be considered if staging disclosed metastases, or if the MCT is grade 3. Radiation Therapy Mast cell tumors are quite sensitive to the effects of radiation therapy, even at moderate doses. Dogs that have no measurable evidence of disease after surgical removal of MCTs but which had incomplete excision on histologic examination of excised tissues (Stage 0), has significantly longer tumor control and survival following radiation therapy than other dogs. Thus, post-surgical radiation therapy for incompletely excised tumors seems beneficial. Mast cell tumors of the extremities often present the greatest challenge for complete surgical excision. For well- or moderately differentiated tumors in these locations, combined modalities of less aggressive surgical debulking followed by radiation therapy may be a more acceptable treatmentboth functionally and cosmetically. Grade 3 MCT: Radiation therapy was used to treat dogs with grade 3 MCT that had only residual microscopic disease after surgery. In all case the regional lymph node was irradiated as well. Local control of the MCT was excellent, with a median remission time of 28 months. More than half of the dogs eventually developed lymph node metastases underscoring the need for systemic therapy in this disease. Palliative radiation therapy: Radiation therapy may alleviate symptoms of extensive or systemic disease. When the tumor is poorly differentiated or metastasis is already confirmed, the use of high-dose intermittent radiation treatments may improve the quality of life by stopping bleeding or reducing the size of a bulky or irritating tumor. In these cases, a fully fractionated course would be costly and reduce the amount of time spent by owners with the dog. A coarsely fractionated series of three 8-Gy treatments on a schedule of day 0, 7, and 21, however, provides relief from symptoms, although it will not increase life span. Systemic therapy, as outlined later, can also be considered. Systemic Therapy Metastatic disease was found to occur more frequently in dogs that had grade 3 MCT, and in dogs that had incomplete surgical excision of their cutaneous tumor. When MCTs have metastasized or spread systemically, localized therapies, such as surgery or radiation, are appropriate only as palliation for discomfort or mechanical obstruction. For these dogs, systemic therapy is required. Corticosteroids are primarily palliative, but some long-term responses do occur. Oral prednisone (2 mg/kg/day for 2 weeks, then 1 mg/kg/day for 2 weeks, then 1 mg/kg every other day) is given as long as the tumor does not progress. Anecdotally, dogs that are tumor-free after six months have a lower incidence of recurrence; therefore, therapy is usually discontinued at this time. Vinblastine and prednisone were used to treat MCTs in one study. The overall response rate in dogs with measurable disease was 47%, there were 5 complete responses and 2 partial responses. The median response duration was 5 months (1 to >22 months). Dogs with lower grade tumors seemed to respond better. Vinblastine is myelosuppressive, and a weekly CBC should be performed prior to administering the drug at this inter-treatment interval. CCNU (Lomustine) at a dose of 90mg/m2 every 4 weeks PO was given to 19 dogs. One dog had a complete response for 15 months, and 7 had a partial response for an average of 3 months (1 to 9 months). This drug can be safely combined with prednisone. If using CCNU, monitor CBC (especially platelet count) and liver enzymes prior to each administration, discontinue if thrombocytopenia or increased liver enzymes are seen. Vincristine was found to be an inactive agent for the treatment of MCT and often causes severe gastrointestinal toxicity. It is not recommended as a first-line chemotherapy agent for the treatment of MCT. Novel Therapies Mutations in the proto-oncogene c-kit were shown to lead to constitutive phosphorylation of the gene product, and are believed to be important in the development and progression of canine MCT.65 There is no evidence that such mutations are breed associated. Abnormalities in c-kit are more common in grade 2 and grade 3 tumors than in grade 1 MCT implying a role in biologic behavior of MCT in dogs. Mutations in one study were seen in more than one-third of dogs with grade 2 or grade 3 MCT. The therapeutic implication of such a finding is that kinase inhibitors may be useful, such as imatinib mesylate (Gleevec) which has been reported to cause clinical remissions in human patients with similar c-kit mutations. Gleevec has anecdotally caused serious morbidity and mortality when used in the dog limiting its clinical usefulness for veterinary medicine. However, clinical trials using drugs with a similar mode of action are underway in canine patients with preliminary encouraging results with one such drug (SU11654). Palliation of Paraneoplastic Symptoms Ancillary drug therapy is important with canine MCTs. Animals with mastocytosis or bulky mast cell disease should receive H2 antagonists, as rapid degranulation of neoplastic mast cells may follow surgery or chemotherapy. Elevated systemic histamine levels may also be seen with recurrent disease. The objective of the therapy is to prevent gastrointestinal ulceration associated with elevated levels of histamine and to treat ulcers already present. This is most likely to occur in dogs with larger, bulky disease, with recurrence of cutaneous disease, or with systemic spread of MCT. Cimetidine reduces gastric acid production by competitive inhibition of the action of histamine on H2 receptors of the gastric parietal cells. Ranitidine or famotidine, H2 antagonists that require less frequent administration, may be used for a similar effect. Omeprazole, which inhibits gastric acid production by the gastric parietal cells through proton pump inhibition, may also be used. Dogs with evidence of gastrointestinal ulceration and bleeding may benefit from sucralfate therapy at a dose of 0.5 to 1.0 g TID PO. Sucralfate reacts with stomach acid to form a highly condensed, viscous, adherent, paste-like substance that binds to the surface of both gastric and duodenal ulcers. The barrier formed protects the ulcer from potential ulcerogenic properties of pepsin, acid, and bile, allowing the ulcer to heal. Such H1 antagonists as diphenhydramine should be considered for use along with cimetidine before and after surgical removal of canine MCTs to help prevent the negative effects
5 of local histamine release on fibroplasia and wound healing. A second generation H1 antagonist, loratadine, has been shown to be very effective at inhibiting histamine release by blocking degranulation from normal canine mast cells, and therefore may be a good choice for palliation of dogs with MCT. Reference List London CA,, et al. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Path 1996;115: Bookbinder PF, Butt MT, Harvey HJ. Determination of the number of mast cells in lymph node, bone marrow, and buffy coat cytologic specimens from dogs. J Am Vet Med Assoc 1992;200: Gieger TL, et al. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases ( ). J Vet Intern Med 2003;17: Murphy S, et al. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 2004;154: Séguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-ii mast cell tumors treated with surgery alone: 55 cases ( ). J Am Vet Med Assoc 2001;218: Cahalane AK, Payne S, Barber LG, et al. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated with surgery with or without adjunctive treatment. 68 cases. J Am Vet Med Assoc 2004;225: Simpson AM, Ludwig LL, Newman SJ, et al. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2004;224: Frimberger AE, Moore AS, LaRue SM, et al. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases ( ). J Am Anim Hosp Assoc 1997;33: Hahn KA, King GK, Carreras JK. Efficacy of radiation therapy for incompletely resected grade-iii mast cell tumors in dogs: 31 cases ( ). J Am Vet Med Assoc 2004;224: Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-- 41 cases ( ). J Vet Intern Med 1999;13: Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-5
What s new for Mast Cell Tumors in Dogs?
What s new for Mast Cell Tumors in Dogs? Pascale C Salah, Dr. vet. med., DACVIM (oncology) Michael Mison, DVM, DACVS Lili Duda, VMD, MBE, DACVR(RO) Amy Durham, MS, VMD, DACVP (Anatomic Pathology) University
More informationCanine Mast Cell Tumors
Canine Mast Cell Tumors By: Dr. Custead WVRC Introduction Mast cells Resident inflammatory cell of the skin, lungs, gastro- intestinal tract Reactions secondary to IgE binding Allergic reactions Granules
More informationINTERACTIVE CASE MANAGEMENT
INTERACTIVE CASE MANAGEMENT A N U D E P R U N G S I P I P A T, D V M ( H O N S ), P H D, D T B V P, C E R T E S A V S ( O N C O L O G Y ) C O M P A N I O N A N I M A L C A N C E R R E S E A R C H U N I
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress WHAT IS THE BEST PROTOCOL FOR CANINE LYMPHOMA? Antony S. Moore, M.V.Sc., Dipl. A.C.V.I.M. (Oncology) Veterinary
More informationNEW PERSPECTIVES WITH CANINE MAST CELL TUMORS Brian Husbands, DVM, Diplomate ACVIM (oncology)
NEW PERSPECTIVES WITH CANINE MAST CELL TUMORS Brian Husbands, DVM, Diplomate ACVIM (oncology) Overview of Canine Mast Cell Tumors Mast cell tumors are the most common canine skin tumor in dogs accounting
More informationMAST CELL TUMORS: TO CUT OR NOT TO CUT
MAST CELL TUMORS: TO CUT OR NOT TO CUT C. Guillermo Couto, DVM, Dip. ACVIM Couto Veterinary Consultants Hilliard, OH 43026 coutovetconsultants@gmail.com Not one of them is like the other, don t ask me
More informationCLINICAL AND PATHOLOGICAL ASPECTS IN 2 CASES OF CANINE MASTOCYTOMA
CLINICAL AND PATHOLOGICAL ASPECTS IN 2 CASES OF CANINE MASTOCYTOMA C. MURESAN 1, P. BOLFA 2, C. CATOI 2, A. GAL 2, M. TAULESCU 2, F. TABARAN 2, A. NAGY 2 1 Emergency Hospital, 2 Discipline of Pathology
More informationMAST CELL TUMORS WHAT IS A MAST CELL?
MAST CELL TUMORS WHAT IS A MAST CELL? Mast cells are found in all tissues of the body. This cell is part of our immunologic defense systems against invading organisms but they are in especially high numbers
More informationMast Cell Tumors in Dogs
Mast Cell Tumors in Dogs 803-808-7387 www.gracepets.com These notes are provided to help you understand the diagnosis or possible diagnosis of cancer in your pet. For general information on cancer in pets
More informationCANINE MAST CELL TUMORS: MARGINS, MARKERS & PROGNOSTIC FACTORS
CANINE MAST CELL TUMORS: MARGINS, MARKERS & PROGNOSTIC FACTORS Philip J. Bergman DVM, MS, PhD, DACVIM (Oncology) Chief Medical Officer, BrightHeart Veterinary Centers Armonk, NY 10504; pbergman@brightheartvet.com
More informationA mast cell, coated with IgE antibodies, is exposed to pollen and degranulates, releasing its biochemical weapons of destruction.
Mast Cell Tumors The Pet Health Care Library What is a Mast Cell? A normal mast cell is part of our immunologic defense systems against invading organisms. Mast cells are meant to participate in the war
More informationMast cell tumors are one of the most. Clinical Management of Mast Cell Tumors in Dogs
Article #4 CE Clinical Management of Mast Cell Tumors in Dogs Tracy Gieger, DVM, DACVIM Nicole Northrup, DVM, DACVIM Michelle Wall, DVM, DACVIM The University of Georgia Now Online: Full-Text Articles
More informationCutaneous mast cell tumours staging and histological grading
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Cutaneous mast cell tumours staging and histological grading Author : MELANIE DOBROMYLSKYJ Categories : Vets Date : September
More informationDEMYSTIFYING CANINE MAST CELL TUMOURS
DEMYSTIFYING CANINE MAST CELL TUMOURS Douglas H. Thamm, VMD, DACVIM (Oncology) INTRODUCTION Mast cell tumor (MCT) represents the most common malignant cutaneous tumor in the dog, and is commonly encountered
More informationDecision making in surgical oncology- when to cut big, when to cut small
Decision making in surgical oncology- when to cut big, when to cut small Simon T. Kudnig, BVSc, MVS, MS, FANZCVSc, Dipl. ACVS ACVS Founding Fellow in Surgical Oncology Animal Referral Hospital, Melbourne,
More informationCanine Cutaneous Melanoma
Canine Cutaneous Melanoma By Elizabeth Downing Clinical Advisor: Dr. Angharad Waite, VMD Basic Science Advisor: Dr. Cheryl Balkman, DVM, DACVIM Senior Seminar Paper Cornell University College of Veterinary
More informationIMPROVING CHEMOTHERAPY AND ITS PROTOCOLS TUMOUR TYPES
Vet Times The website for the veterinary profession https://www.vettimes.co.uk IMPROVING CHEMOTHERAPY AND ITS PROTOCOLS TUMOUR TYPES Author : Frances Taylor Categories : Vets Date : August 29, 2011 Frances
More informationTOP 10 Recent Advances in Veterinary Oncology 1. Six month chemo for lymphoma.1 2. FNA of non-palpable LN s.2
TOP 10 Recent Advances in Veterinary Oncology Philip J. Bergman DVM, MS, PhD Diplomate ACVIM, Oncology Chief Medical Officer BrightHeart Veterinary Centers 80 Business Park Drive, Suite 110, Armonk, NY
More informationPrinciples of Surgical Oncology. Winnie Achilles Tierklinik Hollabrunn Lastenstrasse Hollabrunn
Principles of Surgical Oncology Winnie Achilles Tierklinik Hollabrunn Lastenstrasse 2 2020 Hollabrunn boexi@gmx.de The first surgery provides the best chance for a cure in an animal with a tumor Clinical
More informationUPDATE ON RADIOTHERAPY
1 Miriam Kleiter UPDATE ON RADIOTHERAPY Department for Companion Animals and Horses, Plattform Radiooncology and Nuclear Medicine, University of Veterinary Medicine Vienna Introduction Radiotherapy has
More informationCanine Histiocytic Disorders DR. MEREDITH GAUTHIER, DVM DACVIM (ONCOLOGY) OCTOBER 29, 2015
Canine Histiocytic Disorders DR. MEREDITH GAUTHIER, DVM DACVIM (ONCOLOGY) OCTOBER 29, 2015 Canine Histiocytes! Cells derived from CD34+ stem cells and blood monocytes! Macrophages! Dendritic cells (DC)!
More informationMast cell tumors (MCT) are the most common cutaneous
J Vet Intern Med 2003;17:687 692 Biologic Behavior and Prognostic Factors for Mast Cell Tumors of the Canine Muzzle: 24 Cases (1990 2001) Tracy L. Gieger, Alain P. Théon, Jonathan A. Werner, Margaret C.
More informationOutcomes of Dogs with Grade 3 Mast Cell Tumors: 43 Cases ( )
RETROSPECTIVE STUDIES Outcomes of Dogs with Grade 3 Mast Cell Tumors: 43 Cases (1997 2007) Carrie Tupper Hume, VMD, Diplomate ACVIM*, Matti Kiupel, BS, MS, PhD, Diplomate ACVP, Lora Rigatti, VMD, Frances
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationVeterinary Oncology Consultants, Pty Ltd 379 Lake Innes Drive, Wauchope NSW
Progress in the War on Cancer: New Treatments Dr Angela Frimberger VMD, MANZCVS, Diplomate ACVIM(Onc) Dr Antony Moore BVSc, MVSc, MANZCVS, Diplomate ACVIM(Onc) Veterinary Oncology Consultants, Pty Ltd
More informationSpecialist Referral Service Willows Information Sheets. Cancer in cats and dogs: Assessment of the patient
Specialist Referral Service Willows Information Sheets Cancer in cats and dogs: Assessment of the patient Cancer in cats and dogs: Assessment of the patient Cancer is common in human and veterinary medicine.
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationLymphoma (Lymphosarcoma) by Pamela A. Davol
Lymphoma (Lymphosarcoma) by Pamela A. Davol Cells derived from the bone marrow that mature and take part in cellular immune reactions are called lymphocytes. When lymphocytes undergo transformation and
More informationRadiotherapy in feline and canine head and neck cancer
Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer in companion animals and many clients are well informed
More informationMammary Tumors. by Pamela A. Davol
Mammary Tumors by Pamela A. Davol Malignant tumors of the mammary glands occur with a higher incident than any other form of cancer in female dogs. Additionally, evidence suggests that females with benign
More informationLymphoma in Dogs What You Need to Know
Lymphoma in Dogs What You Need to Know The word cancer elicits many different feelings for people fear, helplessness, and uncertainty just to name a few. Sadly, our fur babies aren t immune from the grips
More informationCutaneous mast cell tumours in canines diagnosis and staging
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Cutaneous mast cell tumours in canines diagnosis and staging Author : KELLY BOWLT, MIKE STARKEY, SUE MURPHY Categories : Vets
More informationIdentification and correlation of cytologic criteria to histologic grade in canine cutaneous mast cell tumors
Retrospective Theses and Dissertations Iowa State University Capstones, Theses and Dissertations 2007 Identification and correlation of cytologic criteria to histologic grade in canine cutaneous mast cell
More informationFundamentals of Surgical Oncology in Small Animals Michael J. Orencole and Ryan Butler, DVM, MS, Diplomate ACVS (Small Animal)
Peer reviewed Fundamentals of Surgical Oncology in Small Animals Michael J. Orencole and Ryan Butler, DVM, MS, Diplomate ACVS (Small Animal) Cancer is one of the major causes of morbidity in veterinary
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationKlinikleitung: Dr. Kessler Dr. Kosfeld Dr. Tassani-Prell Dr. Bessmann. Radiotherapy in feline and canine head and neck cancer.
Radiotherapy in feline and canine head and neck cancer Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationLymphoma. What is cancer? What are signs that my cat has lymphoma. How is Lymphoma diagnosed?
What is cancer? Lymphoma Cancer is the uncontrolled growth of a small population of abnormal cells. These abnormal cells form by a mutation during the normal division cycle and are able to escape detection
More informationImaging of Gastrointestinal Stromal Tumors (GIST) Amir Reza Radmard, MD Assistant Professor Shariati hospital Tehran University of Medical Sciences
Imaging of Gastrointestinal Stromal Tumors (GIST) Amir Reza Radmard, MD Assistant Professor Shariati hospital Tehran University of Medical Sciences Describe the typical imaging findings of GIST at initial
More informationMast cell tumors (MCTs) represent the most common
J Vet Intern Med 1999;13:491 49 Prednisone and Vinblastine Chemotherapy for Canine Mast Cell Tumor 41 Cases (1992 199) Douglas H. Thamm, Elizabeth A. Mauldin, and David M. Vail Forty-one dogs with mast
More informationأملس عضلي غرن = Leiomyosarcoma. Leiomyosarcoma 1 / 5
Leiomyosarcoma 1 / 5 EPIDEMIOLOGY Exact incidence is unknown, but older studies suggest that leiomyosarcomas comprise approximately 3 percent of soft-tissue sarcomas. Superficial leiomyosarcoma occurs
More informationPrinciples of Oncologic Surgery
Principles of Oncologic Surgery Stephen J. Birchard, DVM, MS, Diplomate, ACVS Staff Surgeon, Medvet Toledo Website: Veterinary Key Points, drstephenbirchard@blogspot.com Introduction Surgical oncology
More informationHistiocytic Neoplasms of the Dog and Cat
Histiocytic Neoplasms of the Dog and Cat V.E. Valli DVM Histiocytic and Dendritic Cell Populations Both lineages are bone marrow derived. Macrophages are part of the innate immune system that are phagocytic
More informationTumors of the Spleen
Tumors of the Spleen 803-808-7387 www.gracepets.com These notes are provided to help you understand the diagnosis or possible diagnosis of cancer in your pet. For general information on cancer in pets
More informationMast cell tumors (MCTs) are among the most
J Vet Intern Med 2006;20:933 940 Recurrence Rate, Clinical Outcome, and Cellular Proliferation Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors:
More informationNUCLEAR MORPHOMETRY IN RELATION TO METASTASES IN CANINE SPONTANEOUS CUTANEOUS SQUAMOUS CELL CARCINOMAS
Trakia Journal of Sciences, Vol. 8, No. 1, pp 74-78, 2010 Copyright 2009 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-7050 (print) ISSN 1313-3551 (online) Original Contribution
More informationDa Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction
E-Da Medical Journal 2016;3(2):24-28 Case Report Marjolin s Ulcer: A Case Report and Literature Review Yue-Chiu Su 1, Li-Ren Chang 2 Marjolin s ulcer is an aggressive cutaneous malignancy, which is common
More informationAlmost any suspected tumor can be aspirated easily and safely. Some masses are more risky to aspirate including:
DOES THIS PATIENT HAVE CANCER? USING IN-HOUSE CYTOLOGY TO HELP YOU MAKE THIS DIAGNOSIS. Joyce Obradovich, DVM, Diplomate, ACVIM (Oncology) Animal Cancer & Imaging Center, Canton, Michigan Almost every
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationFaster Cancer Treatment Indicators: Use cases
Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:
More informationEASY APPROACH TO THE PATIENT WITH LYMPHOMA
EASY APPROACH TO THE PATIENT WITH LYMPHOMA C. Guillermo Couto, DVM, dipl. ACVIM Couto Veterinary Consultants, Hilliard, OH 43026 coutovetconsultants@gmail.com Diagnosis Before instituting therapy, the
More informationImmunolight Therapy for Canine Lymphoma Clinical Trial: Client Information
North Carolina State University is a land-grant university and a constituent institution of The University of North Carolina College of Veterinary Medicine Department of Clinical Sciences Immunolight Therapy
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationSTAGING, BIOPSY AND NATURAL HISTORY OF TUMORS SCOTT D WEINER MD
STAGING, BIOPSY AND NATURAL HISTORY OF TUMORS SCOTT D WEINER MD WHAT DO YOU DO WHEN THIS SHOWS UP IN YOUR OFFICE? besides panicking KEY PRINCIPLE!!! Reactive zone is the edema, neovascularity and inflammation
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress THE LAST GASP II: LUNGS AND THORAX David Holt, BVSc, Diplomate ACVS University of Pennsylvania School of Veterinary
More informationMAMMARY GLAND TUMORS General Information Pathology History & Clinical Signs
MAMMARY GLAND TUMORS Philip J. Bergman DVM, MS, PhD, DACVIM (Oncology) Chief Medical Officer, BrightHeart Veterinary Centers, Armonk, NY 10504 pbergman@brightheartvet.com (914) 219-5415 (office), 219-5417
More informationRADIOFREQUENCY ABLATION
RADIOFREQUENCY ABLATION ELIZABETH DAVID M D FRCPC VASCULAR A ND INTERVENTIONAL RADIOLOGIST SUNNYBROOK HEALTH SCIENCES CENTRE GIST GASTROINTESTINAL STROMAL TUMORS Stromal or mesenchymal neoplasms affecting
More informationLymphoma Diagnosis & Treatment
Lymphoma Diagnosis & Treatment Simon Tappin MA VetMB CertSAM DipECVIM-CA MRCVS RCVS & European Specialist in Veterinary Internal Medicine, United Kingdom Introduction What is lymphoma? Why to animal get
More informationAn update to lymphoma in dogs
Vet Times The website for the veterinary profession https://www.vettimes.co.uk An update to lymphoma in dogs Author : James Elliott Categories : Companion animal, Vets Date : November 23, 2015 Lymphoma
More informationMast cell tumors (MCT) are the most common
J Vet Intern Med 2009;23:1051 1057 Ultrasound-Guided Cytology of Spleen and Liver: A Prognostic Tool in Canine Cutaneous Mast Cell Tumor D. Stefanello, P. Valenti, S. Faverzani, V. Bronzo, V. Fiorbianco,
More informationLymphoma accounts for 10-20% of all canine cancers and is by far the most common canine blood cancer.
Lymphoma What is cancer? Cancer is the uncontrolled growth of a small population of abnormal cells. These abnormal cells form by a mutation during the normal division cycle and are able to escape detection
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationWHAT IS YOUR DIAGNOSIS?
WHAT IS YOUR DIAGNOSIS? A six-year and eight-month old, male entire cross breed was presented to the R(D)SVS Cardiopulmonary service for investigation of a 2-week history of tachypnoea. A mediastinal mass
More informationMetastatic mechanism of spermatic cord tumor from stomach cancer
Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi
More informationDavid Bruyette, DVM, DACVIM Medical Director
VCAWLAspecialty.com David Bruyette, DVM, DACVIM Medical Director The pancreas is made up of endocrine and exocrine tissue. The endocrine pancreas is composed of islets of Langerhans, which make up approximately
More informationmostly affects the external lymph nodes. They may or may not involve other organs. But in a vast majority of cases it has been observed that lymphoma
Lymphoma in dogs What is the prognosis for dogs with lymphoma?. lymphoma or lymphosarcoma is one of the most common neoplasms (tumor) in dogs. They usually originate in lymphoid tissues, like the lymph
More informationORAL MELANOMA Definition Epidemiology Clinical Presentation
ORAL MELANOMA Definition Melanoma is a highly malignant neoplasia, arising from melanocytes, the cells that produce the brownish pigment melanin. Melanin is the determinant in skin colour and protects
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More information"The standard treatment for almost all cancers is surgical removal of the lump."
Cancer Treatment As continuous improvements in our knowledge and new and evolving methods of treatment are developed, pet owners and their veterinarians have more options available when cancer is diagnosed.
More informationOsteosarcoma (Canine)
Osteosarcoma (Canine) Answering Your Questions About Osteosarcoma In Dogs What Is Osteosarcoma? Usual Sites for Osteosarcoma Development Osteosarcoma is by far the most common bone tumor of the dog, usually
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationThe Vocabulary of Cancer - By Patricia Long November 20, 2002
The Vocabulary of Cancer - By Patricia Long November 20, 2002 Websites to bookmark: www.cancer.gov www.cancer.org www.vetcancersociety.org www.oncolink.com/templates/types/section.cfm?c=22&s=69 Like any
More informationSo, we already talked about that recognition is the key to optimal treatment and outcome.
Hi, I m Dr. Anthony Lucci from the University of Texas MD Anderson Cancer Center in Houston. And today, I d like to talk to you about the role of surgery in inflammatory breast cancer patients. So, there
More informationMast cell tumor (MCT) is a common neoplasm in dogs,
J Vet Intern Med 2003;17:194 198 Relationship of Disease Progression and Plasma Histamine Concentrations in 11 Dogs with Mast Cell Tumors Taketo Ishiguro, Tsuyoshi Kadosawa, Satoshi Takagi, Gonhyung Kim,
More informationOral Tumors in Dogs Gingival Enlargement
Oral Tumors in Dogs Is that lump you re seeing in your dog s mouth normal? Or is it something to be concerned about? The easiest way to know for sure is to have it evaluated by a veterinarian. When you
More informationLymphoma. Types of Lymphoma. Clinical signs
Lymphoma Lymphoma is a tumour originating from lymphoid tissue, either nodal (lymph ) or extranodal (thymus, spleen, mucosa, conjunctiva, or skin-associated lymphoid tissue). It is one of the most common
More informationMultiorgan Resection (Including the Pancreas) for Metastasis of Cutaneous Malignant Melanoma
MULTIMEDIA ARTICLE - Clinical Imaging Multiorgan Resection (Including the Pancreas) for Metastasis of Cutaneous Malignant Melanoma Tibor Belágyi, Péter Zsoldos, Roland Makay, Ákos Issekutz, Attila Oláh
More informationAssociated Terms: Osteosarcoma, Bone Cancer, Limb Salvage, Appendicular Osteosarcoma, Pathologic Fracture, Chondrosarcoma
1 of 9 9/29/2014 8:25 PM Associated Terms: Osteosarcoma, Bone Cancer, Limb Salvage, Appendicular Osteosarcoma, Pathologic Fracture, Chondrosarcoma The term "ACVS Diplomate" refers to a veterinarian who
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
More informationDISORDERS OF THE BREAST Dated. FIBROADENOSIS Other common names: mastitis, fibrocystic disease, cystic mammary dysplasia.
DISORDERS OF THE BREAST Dated BENIGN BREAST DISORDERS (Essential Surg 2 nd Ed, pp 540) FIBROADENOSIS Other common names: mastitis, fibrocystic disease, cystic mammary dysplasia. Fibroadenosis is the distortion
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma
Nth of Scotland Cancer Netwk Clinical Management Guideline f Malignant Melanoma Based on WOSCAN CMG with further consultation within NOSCAN UNCONTROLLED WHEN PRINTED Prepared by Approved by Issue date
More informationSuccessful Chemotherapeutic Management of TVT in Dogs Report of 24 Cases
IJISET - International Journal of Innovative Science, Engineering & Technology, Vol. 2 Issue 8, August 2015. www.ijiset.com ISSN 2348 7968 Successful Chemotherapeutic Management of TVT in Dogs Report of
More informationLara Kujtan, MD; Abdulraheem Qasem, MD
The Treatment of Lung Cancer Between 2013-2014 at Truman Medical Center: A Retrospective Review in Fulfillment of the Requirements of Standard 4.6 (Monitoring Compliance with Evidence- Based Guidelines)
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationOutcome and Prognostic Factors Following Adjuvant Prednisone/Vinblastine Chemotherapy for High-Risk Canine Mast Cell Tumour: 61 Cases
FULL PAPER Internal Medicine Outcome and Prognostic Factors Following Adjuvant Prednisone/Vinblastine Chemotherapy for High-Risk Canine Mast Cell Tumour: 61 Cases D.H. THAMM 1) *, M.M. TUREK 1) and D.M.
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY
GOAL: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY 1. Understated the role of cytopathology in the clinical management of the patient and recognize
More informationThe histiocytic disorders remain poorly defined in
J Vet Intern Med 2012;26:1164 1168 Histologic and Immunohistochemical Review of Splenic Fibrohistiocytic Nodules in Dogs A.S. Moore, A.E. Frimberger, N. Sullivan, and P.F. Moore Background: Splenic fibrohistiocytic
More informationCurriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center
MEDICAL ONCOLOGY AND HEMATOLOGY (R2, R3) A. The PURPOSE of this rotation is to afford medical residents a broad clinical and training experience in the clinical diagnosis and management of common adult
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More information